All In Biotech

Drug Trial Radar · NCT06516978

A Study Comparing the Efficacy and Safety of Pola-RCHP-X Versus RCHOP-X and Pola-RCHP in Previously Untreated Patients With DLBCL

A Prospective, Open-Label, Multicenter, Randomized Controlled Study Comparing the Efficacy and Safety of Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Combined With Orelabrutinib/Chidamide/Venetoclax/Lenalidomide/PD1 (Pola-RCHP-X) Versus RCHOP-X and Pola-RCHP in Previously Untreated Patients With Diffuse Large B-Cell Lymphoma

Last checked: Nov 20, 2026Latest source record: Jul 24, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 528 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

528

Planned (sponsor's estimate)

Start

Oct 1, 2024

Primary completion

Oct 1, 2028

Study completion Apr 1, 2029

Sponsor

Sponsor type
Academic, hospital or other
First posted
Jul 24, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study aims to compare the efficacy and safety of Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone combined with Orelabrutinib/Chidamide/Venetoclax/Lenalidomide/PD1 (Pola-RCHP-X) versus RCHOP-X and Pola-RCHP in previously untreated patients with DLBCL.

Conditions

  • Diffuse Large B Cell Lymphoma

Interventions

  • Polatuzumab vedotinDrug

    Polatuzumab vedotin IV infusion will be administered as per the schedule specified in the respective arm.

  • RituximabDrug

    Rituximab IV infusion will be administered as per the schedule specified in the respective arm.

  • CyclophosphamideDrug

    Cyclophosphamide IV infusion will be administered as per the schedule specified in the respective arm.

  • DoxorubicinDrug

    Doxorubicin IV infusion will be administered as per the schedule specified in the respective arm.

  • VincristineDrug

    Vincristine IV infusion will be administered as per the schedule specified in the respective arm.

  • PrednisoneDrug

    Prednisone PO will be administered as per the schedule specified in the respective arm.

  • OrelabrutinibDrug

    Orelabrutinib PO will be administered as per the schedule specified in the respective arm.

  • VenetoclaxDrug

    Venetoclax PO will be administered as per the schedule specified in the respective arm.

  • ChidamideDrug

    Chidamide PO will be administered as per the schedule specified in the respective arm.

  • PenpulimabDrug

    Penpulimab IV infusion will be administered as per the schedule specified in the respective arm.

  • LenalidomideDrug

    Lenalidomide PO will be administered as per the schedule specified in the respective arm.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression Free Survival at 24 months (PFS24) Assessed by Investigator per Lugano Response Criteria for Malignant LymphomaTime frame: At 24 months

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.